02/24/2026
Big moment for psychedelic medicine!
Compass Pathways just hit the primary endpoint in its second Phase 3 trial of COMP360 psilocybin for treatment-resistant depression. The findings? Significant symptom reduction, rapid onset, and effects lasting up to 26 weeks after just one or two doses. 🙌🏼
With strong safety protocols and FDA discussions underway, the future of mushroom-inspired mental health care is moving closer to mainstream reality.
The momentum is real! Mushrooms ARE the future.